We are live on
!
Find out more
Westfield Capital Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
49.45%
This Fund
S&P 500
This Quarter
Est. Return
+19.96%
1 Year Est. Return
+49.45%
3 Year Est. Return
+148.08%
5 Year Est. Return
+180.9%
10 Year Est. Return
+972.69%
AUM
$13.1B
AUM Growth
+$1.42B
(+12%)
Cap. Flow
-$642M
Cap. Flow
% of AUM
-4.89%
Top 10 Holdings %
Top 10 Hldgs %
18.52%
Holding
284
New
44
Increased
49
Reduced
142
Closed
38
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$163M |
| 2 |
Caterpillar
CAT
|
+$85.4M |
| 3 |
Analog Devices
ADI
|
+$53.7M |
| 4 |
Advance Auto Parts
AAP
|
+$39.7M |
| 5 |
FISV
Fiserv Inc
FISV
|
+$37.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$142M |
| 2 |
Costco
COST
|
+$77.5M |
| 3 |
Vail Resorts
MTN
|
+$76.9M |
| 4 |
CELG
Celgene Corp
CELG
|
+$73.2M |
| 5 |
Mettler-Toledo International
MTD
|
+$67.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.26% |
| 2 | Healthcare | 16.35% |
| 3 | Consumer Discretionary | 13.11% |
| 4 | Industrials | 12.97% |
| 5 | Financials | 10.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DAY
176
DELISTED
Dayforce
DAY
| $19M | 0.14% |
+370,147
| New | +$16.4M |
|
177
Ralph Lauren
RL
$23.5B
| $18.4M | 0.14% |
+141,588
| New | +$16.9M |
|
|
CTLT
178
DELISTED
CATALENT, INC.
CTLT
| $18.2M | 0.14% |
448,946
+101,645
| +29% | +$3.97M |
|
179
STAG Industrial
STAG
$7.13B
| $18.1M | 0.14% |
+611,551
| New | +$16.9M |
|
180
Strategy Inc
MSTR
$39B
| $17.6M | 0.13% |
+1,219,710
| New | +$16.9M |
|
|
MNTA
181
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $17.5M | 0.13% |
1,206,964
+569,604
| +89% | +$7.28M |
|
|
IPHI
182
DELISTED
INPHI CORPORATION
IPHI
| $17.3M | 0.13% |
395,630
-19,240
| -5% | -$765K |
|
183
Hamilton Lane
HLNE
$5.59B
| $16.5M | 0.13% |
379,266
+21,534
| +6% | +$888K |
|
184
CME Group
CME
$95.3B
| $16.2M | 0.12% |
98,224
+22,487
| +30% | +$3.98M |
|
185
Orion
OEC
$408M
| $16M | 0.12% |
840,281
-12,399
| -1% | -$311K |
|
|
WMGI
186
DELISTED
Wright Medical Group Inc
WMGI
| $15.8M | 0.12% |
501,801
-27,413
| -5% | -$832K |
|
187
Fate Therapeutics
FATE
$293M
| $15.7M | 0.12% |
893,425
-210,880
| -19% | -$3.33M |
|
|
CONE
188
DELISTED
CyrusOne Inc Common Stock
CONE
| $15.7M | 0.12% |
+298,715
| New | +$15.6M |
|
|
CORV
189
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
| $15.1M | 0.12% |
4,788,032
+50,228
| +1% | +$162K |
|
190
NovoCure
NVCR
$1.88B
| $14.7M | 0.11% |
305,185
-380,705
| -56% | -$18.3M |
|
|
APLS
191
DELISTED
Apellis Pharmaceuticals
APLS
| $14.3M | 0.11% |
731,451
-36,425
| -5% | -$573K |
|
192
Alarm.com
ALRM
$2.79B
| $13.7M | 0.1% |
211,148
-10,665
| -5% | -$647K |
|
193
Paylocity
PCTY
$8.17B
| $13.6M | 0.1% |
+152,484
| New | +$11.8M |
|
|
RHT
194
DELISTED
Red Hat Inc
RHT
| $11.1M | 0.08% |
60,656
-267,956
| -82% | -$48M |
|
|
CBAY
195
DELISTED
Cymabay Therapeutics
CBAY
| $11.1M | 0.08% |
834,330
-241,885
| -22% | -$2.57M |
|
196
Teladoc Health
TDOC
$1.3B
| $10.9M | 0.08% |
+196,580
| New | +$12M |
|
197
Abbott
ABT
$186B
| $10.8M | 0.08% |
134,625
-4,525
| -3% | -$337K |
|
|
SMAR
198
DELISTED
Smartsheet Inc.
SMAR
| $9.38M | 0.07% |
229,998
-256,970
| -53% | -$8.88M |
|
|
ORTX
199
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $9.35M | 0.07% |
+52,269
| New | +$7.86M |
|
200
Walmart Inc
WMT
$891B
| $9.34M | 0.07% |
287,370
-7,935
| -3% | -$257K |
|
Similar funds
OAG
JG
CHP
SC
Westfield Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Westfield Capital Management held 284 positions worth $13.1B, up 12% from $11.7B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Westfield Capital Management withdrew a net $642M in Q1 2019, closing 38 positions and reducing 142 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $142M position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Westfield Capital Management opened a new position in Bristol-Myers Squibb worth $156M.
- Westfield Capital Management's largest Q1 2019 buy was Bristol-Myers Squibb: 3,278,241 shares worth $156M.
- Westfield Capital Management added most to T-Mobile US in Q1 2019, an estimated $32.3M increase.
- Westfield Capital Management's biggest Q1 2019 reduction was Vail Resorts, cutting an estimated $76.9M.
- Westfield Capital Management fully exited Jazz Pharmaceuticals in Q1 2019, selling an estimated $142M.
- Westfield Capital Management's ten largest holdings make up 19% of its $13.1B portfolio in Q1 2019.
- Westfield Capital Management opened 44 new positions and closed 38 in Q1 2019.
- Westfield Capital Management's portfolio value rose 12% quarter-over-quarter to $13.1B.
Based on Westfield Capital Management's 13F filing for Q1 2019, filed 14 May 2019.